BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35955624)

  • 1. Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.
    Xu L; Shao F; Luo T; Li Q; Tan D; Tan Y
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma.
    Wang L; He S; Tu Y; Ji P; Zong J; Zhang J; Feng F; Zhao J; Gao G; Zhang Y
    J Clin Neurosci; 2013 Jul; 20(7):958-63. PubMed ID: 23707602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer Analysis Identifies AIMP2 as a Potential Biomarker for Breast Cancer.
    Qiu J; Zhou T; Wang D; Hong W; Qian D; Meng X; Liu X
    Curr Genomics; 2023 Dec; 24(5):307-329. PubMed ID: 38235352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
    Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT
    Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR‑500a‑5p promotes glioblastoma cell proliferation, migration and invasion by targeting chromodomain helicase DNA binding protein 5.
    Liu Z; Su D; Qi X; Ma J
    Mol Med Rep; 2018 Sep; 18(3):2689-2696. PubMed ID: 30015879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.
    Garcia I; Mayol G; Rodríguez E; Suñol M; Gershon TR; Ríos J; Cheung NK; Kieran MW; George RE; Perez-Atayde AR; Casala C; Galván P; de Torres C; Mora J; Lavarino C
    Mol Cancer; 2010 Oct; 9():277. PubMed ID: 20950435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A Biomarker for Cancers.
    Yang L; Wei J; Ma X; Cheng R; Zhang H; Jin T
    Oncology; 2024; 102(2):168-182. PubMed ID: 37699361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma.
    Du X; Wu T; Lu J; Zang L; Song N; Yang T; Zhao H; Wang S
    Clin Transl Oncol; 2013 Mar; 15(3):198-204. PubMed ID: 22855185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of APOBEC3C in modulating the tumor microenvironment and stemness properties of glioma: evidence from pancancer analysis.
    Zhang S; Guo Y; Hu Y; Gao X; Bai F; Ding Q; Hou K; Wang Z; Sun X; Zhao H; Qu Z; Xu Q
    Front Immunol; 2023; 14():1242972. PubMed ID: 37809064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromodomain Helicase DNA-Binding Protein 5 Inhibits Renal Cell Carcinoma Tumorigenesis by Activation of the p53 and RB Pathways.
    Huang S; Yan Q; Xiong S; Peng Y; Zhao R; Liu C
    Biomed Res Int; 2020; 2020():5425612. PubMed ID: 33062682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma.
    Higashi M; Kolla V; Iyer R; Naraparaju K; Zhuang T; Kolla S; Brodeur GM
    Mol Cancer; 2015 Aug; 14():150. PubMed ID: 26245651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5.
    Cai C; Ashktorab H; Pang X; Zhao Y; Sha W; Liu Y; Gu X
    PLoS One; 2012; 7(1):e29750. PubMed ID: 22235338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
    Hall WA; Petrova AV; Colbert LE; Hardy CW; Fisher SB; Saka B; Shelton JW; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Volkan Adsay N; Curran WJ; Landry JC; Maithel SK; Yu DS
    Oncogene; 2014 Nov; 33(47):5450-6. PubMed ID: 24276239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CHD5 in human cancers: 10 years later.
    Kolla V; Zhuang T; Higashi M; Naraparaju K; Brodeur GM
    Cancer Res; 2014 Feb; 74(3):652-8. PubMed ID: 24419087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis reveals NUP37 as a prognostic biomarker correlated with the immunosuppressive microenvironment in glioma.
    He Y; Li J; Shen L; Zhou H; Fei W; Zhang G; Li Z; Wang F; Wen Y
    Aging (Albany NY); 2022 Jan; 14(2):1033-1047. PubMed ID: 35093934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma.
    Wang J; Chen H; Fu S; Xu ZM; Sun KL; Fu WN
    Oral Oncol; 2011 Jul; 47(7):601-8. PubMed ID: 21636313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.